Transmission of canine gastric Helicobacter salomonis infection from dam to offspring and between puppies.
H. bizzozeronii CCUG 35045, a new canine gastric Helicobacter spp. was used for experimental infection of four weaned puppies at 7 weeks of age. Controls were four nonchallenged puppies. The puppies originated from two dams which had Helicobacter salomonis infection in biopsy samples taken 3 weeks before the delivery but which had urease, brush cytology and culture-negative biopsy samples taken 7 weeks after antimicrobial treatment (metronidazole, amoxicillin, bismuth subcitrate). Both dams were detected urease- and Helicobacter-positive again three and a half months after therapy. Dam B was shown to be colonised with the similar genotype of H. salomonis for more than 2 years. Unexpectedly, H. salomonis was also cultured from gastric biopsy samples of the nonchallenged puppies three times during 7 months. When H. salomonis isolates of dams and puppies were studied by ribotyping (HaeIII, ClaI or PstI) they were shown to be identical although the HaeIII and PstI REA patterns of dam A differed from the patterns of dam B and nonchallenged group by one fragment. PFGE pattern analysis of NotI digests, however, revealed that the isolates of the puppies were identical with the isolates of dam B, and differed from the isolates of dam A. The isolates of the dams and puppies in the nonchallenged group were metronidazole-resistant. The antimicrobial therapy had merely suppressed, but not eradicated, the infection from dams. These studies suggested that puppies may acquire gastric Helicobacter infection from dams during the lactation period and puppies can infect each other during their early life. PFGE pattern analysis was shown to be a more distinguishing method than ribotyping to study the similarity of the isolates.
Hänninen
M L
ML
Department of Food and Environmental Hygiene, Faculty of Veterinary Medicine, University of Helsinki, Finland. marja-liisa.hanninen@helsinki.fi
Happonen
I
I
Jalava
K
K
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001706:Biopsy / Q000662:veterinary; D004195:Disease Models, Animal; D004283:Dog Diseases / Q000382:microbiology / Q000635:transmission*; D004285:Dogs; D004587:Electrophoresis, Agar Gel / Q000662:veterinary; D016521:Electrophoresis, Gel, Pulsed-Field / Q000662:veterinary; D005243:Feces / Q000382:microbiology; D005260:Female; D005753:Gastric Mucosa / Q000382:microbiology* / Q000503:physiopathology; D016998:Helicobacter / Q000145:classification* / Q000187:drug effects / Q000235:genetics; D016481:Helicobacter Infections / Q000382:microbiology / Q000635:transmission / Q000662:veterinary*; D008795:Metronidazole / Q000494:pharmacology; D015347:RNA Probes; D015183:Restriction Mapping / Q000662:veterinary; D013272:Stomach Diseases / Q000382:microbiology / Q000662:veterinary*
D000900:Anti-Bacterial Agents; D015347:RNA Probes; D008795:Metronidazole